Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study
Phase 1 trial demonstrates strong efficacy and safety for BGB-16673 in relapsed/refractory Waldenström macroglobulinemia, suggesting a promising treatment option.
Key Points
Efficacy results show a major response rate of 64.3% in relapsed/refractory Waldenström macroglobulinemia patients.
Safety profile includes treatment-emergent adverse events observed in 97.6% of patients, with significant neutropenia in 38.1%.
Ongoing phase 1 trial assesses the maximum tolerated dose and tumor regression of BGB-16673 in B-cell malignancies.
Ongoing enrollment highlights potential for BGB-16673 to address unmet needs in heavily pretreated patients with specific mutations.